Clinical Trials Sponsored by Altacor Ltd.

Total 17086 results

Altacor Ltd.

Completed

Antimicrobial Efficacy of ALT005 Ophthalmic Prep Solution in Healthy Volunteers

Infection Secondary to Surgical Procedure

United States
AtaCor Medical, Inc.

Completed

Parasternal Access for ShockS and Pacing With an acUtely Placed Less-invasive Lead for EV-ICD (PASS PULL EV-ICD) Study (PASS PULL)

Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Arrhythmia

Paraguay
Acticor Biotech

Active, not recruiting

ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo (ACTISAVE)

Acute Ischemic Stroke

United States, Germany
AtaCor Medical, Inc.

Recruiting

Subcostal Temporary Extravascular Pacing V Study (STEP V)

Conduction Defect

Paraguay
AtaCor Medical, Inc.

Completed

Sensing and Defibrillation With a Commercially Available ICD Coupled With a Parasternal Extravascular Lead (SECURE EV) Study (SECURE EV)

Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Arrhythmia

Paraguay
AtaCor Medical, Inc.

Completed

Subcostal Temporary Extracardiac Pacing Study (STEP)

Conduction Defect

Paraguay
AtaCor Medical, Inc.

Recruiting

Pilot evaluatIon Of NovEl tEmpoRary ExtraVascular PACING (PIONEER EV PACING) Study

Conduction Defect

Croatia, Czechia
AtaCor Medical, Inc.

Completed

Sub Chronic Evaluation for ATP With an Extravascular Placed ICD Lead (STEP ICD) Study

Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Arrythmia

Paraguay
AtaCor Medical, Inc.

Completed

Subcostal Temporary Extravascular Pacing IV (STEP IV) Study (STEP IV)

Conduction Defect

Paraguay
AtaCor Medical, Inc.

Completed

AtaCor Subcostal Temporary Extravascular Pacing III Study (STEP III)

Conduction Defect

New Zealand, Paraguay, Czechia
AtaCor Medical, Inc.

Completed

Subcostal Temporary Extracardiac Pacing II Study (STEP II)

Conduction Defect

New Zealand, Paraguay
Altaco XXI, LLP
Duke University

Completed

A Study of Allogeneic Low Oxygen Mesenchymal Bone Marrow Cells in Subjects With Myocardial Infarction

Myocardial Infarction

Kazakhstan
Peryam & Kroll Research Corporation
Alticor Inc.

Completed

Assess the Effects of a 30 Day-wellness Program on Digestive Health, Weight and Overall Well-being

Digestive Health

United States
Acticor Biotech

Completed

Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19 (GARDEN)

COVID-19 | Acute Respiratory Distress Syndrome | ARDS | SARS-CoV Infection

France
Acticor Biotech

Completed

Acute Ischemic Stroke Interventional Study (ACTIMIS)

Acute Ischemic Stroke

France
Altor BioScience

Terminated

QUILT-3.002: ALT-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma

United States
Altor BioScience

Completed

Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies

Progressive Metastatic Malignancies

United States
Altair Therapeutics, Inc.

Completed

A Phase 1 Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma (AIR645-CS1)

Asthma

United States
Altor BioScience

Terminated

PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14)

Pharmacokinetics

United States
Altor BioScience

Completed

QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel

Advanced Pancreatic Cancer

United States
Altor BioScience

Completed

A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors

Malignant Solid Tumour | Locally Advanced Malignant Neoplasm

United States
Alteco Medical AB

Withdrawn

Remove LPS Registry

Suspected or Diagnosed Endotoxemia Casued by Gram-negative Bacteria
Altair Therapeutics, Inc.

Completed

Study Evaluating the Effects of AIR645 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma

Asthma

Canada
Altor BioScience

Completed

QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803

Healthy

United States
Mayo Clinic
AtCor Medical, Inc.

Completed

Strategies for Aggressive Central Afterload Reduction in Patients With Heart Failure (SACAR)

Heart Failure

United States
Mount Carmel Health System
AtCor Medical, Inc.

Recruiting

CONNEQT Pulse Validation Study

Pregnancy Related | Pre-Eclampsia | Gestational Hypertension

United States
NHS Greater Glasgow and Clyde
Altair Medical; Storm ID

Unknown

COVID-19 Advanced Respiratory Physiology (CARP) Study (CARP)

Covid19 | Respiratory Failure | Biosensor

United Kingdom
Alteco Medical AB
Uppsala University; TFS Trial Form Support

Terminated

ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber (ASSET)

Septic Shock

Finland, Norway, Sweden
Altor BioScience
Genentech, Inc.; Tanox

Completed

Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome

Sepsis | Acute Respiratory Distress Syndrome | Acute Lung Injury

United States, Canada
Altor BioScience
National Cancer Institute (NCI)

Unknown

QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

United States
Altor BioScience
National Cancer Institute (NCI)

Terminated

QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

United States
Altor BioScience
M.D. Anderson Cancer Center

Withdrawn

ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Altor BioScience
National Cancer Institute (NCI)

Completed

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Transitional Cell Carcinoma of Bladder | Urethra Cancer | Ureter Cancer | Malignant Tumor of Renal Pelvis

United States
Altor BioScience
National Cancer Institute (NCI)

Completed

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Altor BioScience
National Cancer Institute (NCI)

Completed

QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
Medical University of South Carolina
Altor BioScience

Completed

ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
University of Arkansas
Bristol-Myers Squibb; Altor BioScience

Withdrawn

2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)

Multiple Myeloma

United States
Mirka Ltd
Clinius Ltd

Completed

A Pre-market Study to Evaluate the Performance and Safety of a Skin Preparation Device for Removal of Dry Crusty Skin

Keratosis, Actinic | Hyperkeratotic Callus | Actinic Lesion | Solar Keratosis/Sunburn | Hyperkeratosis | Hyperkeratotic; Lesion | Hyperkeratotic Actinic Keratosis

Finland
Salus Ltd.
TheraVitae Ltd.

Completed

Autologous Angiogenic Cell Precursors (ACPs) for the Treatment of Peripheral Artery Disease

Critical Limb Ischemia

Hungary
Altor BioScience
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome

Sepsis | Acute Respiratory Distress Syndrome | Acute Lung Injury

United States
Janssen-Cilag Farmaceutica Ltda.
Janssen Korea, Ltd., Korea

No longer available

An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Hong Kong, Brazil, Thailand
Paion UK Ltd.
Chiltern International Ltd.; HFL Ltd.

Completed

An Efficacy and Safety Study to Compare Morphine 6-glucuronide (M6G) and Morphine in Patients Suffering With Post-Operative Pain for at Least 24 Hours

Postoperative Pain

France, Germany, Netherlands, Poland, United Kingdom, Czechia
Altor BioScience
James and Esther King Biomedical Research Program

Unknown

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer

United States
Calcivis Ltd
Medsource UK Ltd.

Completed

Caries Lesion Activity in Orthodontic Patients - Calcivis System

Dental Caries

United Kingdom
Cardiovalve Ltd.
Meditrial Europe Ltd.

Recruiting

Cardiovalve Transfemoral System - FIM Study

Mitral Regurgitation

Lithuania
Vensica Therapeutics Ltd.
Blueclinical, Ltd.

Completed

Clinical Trial for the Assessment of Safety, Usability and Efficacy of the Vixe Combination for OAB in Female Subjects (XAVIER)

Overactive Bladder

Portugal
Nanomedic Technologies Ltd.

Completed

Evaluation of the SpinCare™ System in the Treatment of Partial Thickness Burns (SPINCARE2)

Partial Thickness Burn

Israel
Nanomedic Technologies Ltd.

Completed

Evaluation of the SPINNER Device for the Application of Wound Dressing: Treatment of Split Skin Graft Donor Sites (SPINNER01)

Wound of Skin

Israel
Danisco
4Pharma Ltd.; Medfiles Ltd.

Completed

Next Generation Probiotics (NGPs) for Metabolic Health

Microbial Colonization
Calcivis Ltd
Medsource UK Ltd.

Completed

Safety and Performance Evaluation of the Calcivis System

Dental Caries

United Kingdom

Clinical Trials Sponsored by Altacor Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations